Kodiak Sciences Beheer

Beheer criteriumcontroles 2/4

De CEO Kodiak Sciences' is Victor Perlroth, benoemd in Jun2009, heeft een ambtstermijn van 13.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 113.37M, bestaande uit 0.6% salaris en 99.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 5.06% van de aandelen van het bedrijf, ter waarde MX$ 218.52M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 4.8 jaar.

Belangrijke informatie

Victor Perlroth

Algemeen directeur

US$113.4m

Totale compensatie

Percentage CEO-salaris	0.6%
Dienstverband CEO	13.8yrs
Eigendom CEO	5.1%
Management gemiddelde ambtstermijn	3.9yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Victor Perlroth's beloning veranderd ten opzichte van Kodiak Sciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2022	n/a	n/a	-US$334m
Sep 30 2022	n/a	n/a	-US$357m
Jun 30 2022	n/a	n/a	-US$347m
Mar 31 2022	n/a	n/a	-US$312m
Dec 31 2021	US$113m	US$655k	-US$267m
Sep 30 2021	n/a	n/a	-US$220m
Jun 30 2021	n/a	n/a	-US$189m
Mar 31 2021	n/a	n/a	-US$159m
Dec 31 2020	US$9m	US$591k	-US$133m
Sep 30 2020	n/a	n/a	-US$102m
Jun 30 2020	n/a	n/a	-US$78m
Mar 31 2020	n/a	n/a	-US$64m
Dec 31 2019	US$18m	US$526k	-US$47m
Sep 30 2019	n/a	n/a	-US$46m
Jun 30 2019	n/a	n/a	-US$44m
Mar 31 2019	n/a	n/a	-US$41m
Dec 31 2018	US$6m	US$428k	-US$41m
Sep 30 2018	n/a	n/a	-US$38m
Jun 30 2018	n/a	n/a	-US$32m
Mar 31 2018	n/a	n/a	-US$31m
Dec 31 2017	US$824k	US$388k	-US$28m

Compensatie versus markt: De totale vergoeding ($USD 113.37M ) Victor } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 447.61K ).

Compensatie versus inkomsten: De vergoeding van Victor is gestegen terwijl het bedrijf verliesgevend is.

CEO

Victor Perlroth (49 yo)

13.8yrs

Tenure

US$113,371,207

Compensatie

Dr. Victor Perlroth, M.D co-founded Kodiak Sciences Inc. in 2009 and serves as its co-founder, Chairman, President and Chief Executive Officer. Dr. Perlroth serves as Chief Executive officer since June 200...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Victor Perlroth	Co-Founder	13.8yrs	US$113.37m	5.06% MX$ 218.5m
John Borgeson	Senior VP	8.8yrs	US$27.87m	0.33% MX$ 14.4m
Jason Ehrlich	Chief Medical Officer & Chief Development Officer	4.6yrs	US$27.95m	0.11% MX$ 4.7m
Michael Louie	Senior VP of Digital Transformation & Chief Information Officer	1.2yrs	geen gegevens	geen gegevens
Hong Liang	Senior Vice President of Discovery Medicine	5.5yrs	US$321.91k	geen gegevens
Stephen Raillard	Senior Vice President of Chemical Development & Manufacturing	less than a year	geen gegevens	geen gegevens
Almas Qudrat	Senior Vice President of Quality Operations	3.3yrs	geen gegevens	geen gegevens
J. Velazquez-Martin	Senior Vice President of Clinical Research & Translational Medicine	less than a year	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

49.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van KOD * wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Victor Perlroth	Co-Founder	13.8yrs	US$113.37m	5.06% MX$ 218.5m
Robert Profusek	Lead Independent Director	4.8yrs	US$471.07k	0.019% MX$ 829.4k
Felix Baker	Independent Director	7.6yrs	US$389.82k	0% MX$ 0
Richard Levy	Independent Director	4.8yrs	US$436.07k	0.0019% MX$ 82.9k
Bassil Dahiyat	Independent Director	4.8yrs	US$442.18k	0% MX$ 0
Charles Bancroft	Independent Director	3yrs	US$460.97k	0.050% MX$ 2.2m
David Boyer	Scientific Advisor	no data	geen gegevens	geen gegevens
Michael IP	Scientific Advisor	no data	geen gegevens	geen gegevens
Sunil Patel	Scientific Advisor	no data	geen gegevens	geen gegevens
David Brown	Scientific Advisor	no data	geen gegevens	geen gegevens
Carl Regillo	Scientific Advisor	no data	geen gegevens	geen gegevens
Pravin Dugel	Scientific Advisor	no data	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van KOD * wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Kodiak Sciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Kodiak Sciences Inc. Announces Executive Appointments

Kodiak Sciences Inc., Annual General Meeting, Jun 04, 2024

Jason Ehrlich, M.D., Ph.D., Informs Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Jason Ehrlich, M.D., Ph.D., Informes Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Co-Founder recently sold Mex$251m worth of stock

Recent updates

Kodiak Sciences Inc. Announces Executive Appointments

Kodiak Sciences Inc. Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

Kodiak Sciences Inc. Announces Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Kodiak Sciences Inc., Annual General Meeting, Jun 04, 2024

Kodiak Sciences Inc. to Report Q4, 2023 Results on Mar 28, 2024

Kodiak Sciences Inc. Announces Presentation of Primary Endpoint Data from Tarcocimab Tedromer Phase 3 Glow Study in Patients with Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting

Kokak Sciences Inc. Announces Top-Line, One-Year Results for Its ABC Platform Based Investigational Therapy Tarcocimab Tedromer 5 Mg from the Pivotal Beacon Study

Jason Ehrlich, M.D., Ph.D., Informs Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Jason Ehrlich, M.D., Ph.D., Informes Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

Kodiak Sciences Reports Positive Topline Results from Beacon Phase 3 Study of Tarcocimab Tedromer (Ksi-301) in Patients with Retinal Vein Occlusion

Kodiak Sciences Inc. Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy

Kodiak Sciences Inc.(NasdaqGM:KOD) dropped from Russell 2000 Growth Index

Co-Founder recently sold Mex$251m worth of stock

Kodiak Sciences Inc. Announces Top-Line Results from Its Initial Phase 2B/3 Study of KSI-301 in Patients with Neovascular Age-Related Macular Degeneration

Kodiak Sciences Inc. Completes Enrollment in Gleam and Glimmer Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

Kodiak Sciences Inc. Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion

Forecast to breakeven in 2025

Forecast to breakeven in 2024

Kodiak Sciences Inc. Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1B Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting

Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences Inc. to Report Q3, 2020 Results on Nov 09, 2020

Kodiak Sciences Inc. Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd